These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37160957)

  • 1. Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.
    Watson CM; Dammer EB; Ping L; Duong DM; Modeste E; Carter EK; Johnson ECB; Levey AI; Lah JJ; Roberts BR; Seyfried NT
    Sci Data; 2023 May; 10(1):261. PubMed ID: 37160957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
    Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zhou M; Haque RU; Dammer EB; Duong DM; Ping L; Johnson ECB; Lah JJ; Levey AI; Seyfried NT
    Clin Proteomics; 2020; 17():19. PubMed ID: 32514259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
    Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J
    J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.
    Lim B; Tsolaki M; Soosaipillai A; Brown M; Zilakaki M; Tagaraki F; Fotiou D; Koutsouraki E; Grosi E; Prassas I; Diamandis EP
    Clin Chem Lab Med; 2019 Nov; 57(12):1875-1881. PubMed ID: 31415236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.
    van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE
    Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression.
    Begcevic I; Tsolaki M; Brinc D; Brown M; Martinez-Morillo E; Lazarou I; Kozori M; Tagaraki F; Nenopoulou S; Gkioka M; Lazarou E; Lim B; Batruch I; Diamandis EP
    F1000Res; 2018; 7():1012. PubMed ID: 30191060
    [No Abstract]   [Full Text] [Related]  

  • 13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
    Libiger O; Shaw LM; Watson MH; Nairn AC; Umaña KL; Biarnes MC; Canet-Avilés RM; Jack CR; Breton YA; Cortes L; Chelsky D; Spellman DS; Baker SA; Raghavan N; Potter WZ; ;
    Alzheimers Dement; 2021 Dec; 17(12):1976-1987. PubMed ID: 33984181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.